Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation

Transplant Immunology

Volumn 32, Issue 2, 2015, Pages 66-71

  Malheiro, Jorge ^a,b   Tafulo, Sandra ^c   Dias, Leonídio ^a   Martins, La Salete ^a,b   Fonseca, Isabel ^a,b   Beirão, Idalina ^a,b   Castro Henriques, António ^a,b   Cabrita, António ^a  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c Centro Do Sangue e Transplantação Do Porto   (Portugal)

Author keywords

Antibody mediated rejection; Donor specific antibody; Graft survival; Kidney transplantation; Single antigen bead assay

Indexed keywords

BASILIXIMAB; HLA ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; ALLOANTIBODY; HLA ANTIGEN;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; DONOR; DRUG DOSE REDUCTION; FEMALE; GRAFT SURVIVAL; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GRAFT REJECTION; IMMUNOLOGY; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 84926417954     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2015.01.002     Document Type: Article

References (27)

1. Mohan S., Palanisamy A., Tsapepas D., Tanriover B., Crew R.J., Dube G., et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012, 23(12):2061-2071.
2. Tait B.D., Susal C., Gebel H.M., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013, 95(1):19-47.
3. Amico P., Honger G., Mayr M., et al. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009, 87(11):1681-1688.
4. Caro-Oleas J.L., Gonzalez-Escribano M.F., Gonzalez-Roncero F.M., Acevedo-Calado M.J., Cabello-Chaves V., Gentil-Govantes M.Á., et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant 2012, 27(3):1231-1238.
5. Lefaucheur C., Loupy A., Hill G.S., et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010, 21(8):1398-1406.
6. Lefaucheur C., Suberbielle-Boissel C., Hill G.S., et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008, 8(2):324-331.
7. Otten H.G., Verhaar M.C., Borst H.P., Hené R.J., van Zuilen A.D. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012, 12(6):1618-1623.
8. Tsapepas D.S., Vasilescu R., Tanriover B., et al. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation. Transplantation 2014, 97(6):642-647.
9. Willicombe M., Brookes P., Santos-Nunez E., et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2011, 11(3):470-477.
10. Aubert V., Venetz J.P., Pantaleo G., Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009, 70(8):580-583.
11. Phelan D., Mohanakumar T., Ramachandran S., et al. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009, 70(8):584-588.
12. Mujtaba M.A., Goggins W., Lobashevsky A., Sharfuddin A.A., Yaqub M.S., Mishler D.P., et al. The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients. Clin Transplant 2011, 25(1):E96-E102.
13. Higgins R., Lowe D., Hathaway M., et al. Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 2011, 92(8):900-906.
14. Zhang X., Reed E.F. Effect of antibodies on endothelium. Am J Transplant 2009, 9(11):2459-2465.
15. Jindra P.T., Zhang X., Mulder A., et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006, 82(1 Suppl.):S33-S35.
16. Klitz W., Maiers M., Spellman S., Baxter-Lowe L.A., Schmeckpeper B., Williams T.M., et al. New HLA haplotype frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. Tissue Antigens 2003, 62(4):296-307.
17. Dunn T.B., Noreen H., Gillingham K., et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011, 11(10):2132-2143.
18. Gupta A., Iveson V., Varagunam M., et al. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: are they relevant?. Transplantation 2008, 85(8):1200-1204.
19. Loupy A., Suberbielle-Boissel C., Zuber J., Anglicheau D., Timsit M.O., Martinez F., et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010, 89(11):1403-1410.
20. Gloor J.M., Cosio F.G., Rea D.J., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006, 6(8):1841-1847.
21. Mauiyyedi S., Pelle P.D., Saidman S., Collins A.B., Pascual M., Tolkoff-Rubin N.E., et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001, 12(3):574-582.
22. Marfo K., Ajaimy M., Colovai A., et al. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies. Transplantation 2014, 98(10):1082-1088.
23. Bentall A., Cornell L.D., Gloor J.M., Park W.D., Gandhi M.J., Winters J.L., et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013, 13(1):76-85.
24. Singh N., Djamali A., Lorentzen D., Pirsch J.D., Leverson G., Neidlinger N., et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010, 90(10):1079-1084.
25. Eng H.S., Bennett G., Tsiopelas E., Lake M., Humphreys I., Chang S.H., et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008, 8(11):2335-2342.
26. Zachary A.A., Leffell M.S. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008, 69(10):591-604.
27. Zachary A.A., Sholander J.T., Houp J.A., Leffell M.S. Using real data for a virtual crossmatch. Hum Immunol 2009, 70(8):574-579.